T/FIF, a New Plateau Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (104)	5/5/2000 10:41:00 AM
From: JOEBT1	Read Replies (2) of 2243

Richard-I suspect that with your omnivorous consumption of biotech info your totally up to date on IMGN. However in case you're not---IMGN has a TAP technology platform deal cooking with Cornell/BLZ (plus another partner) who have a PSA antibody. In mice models they demonstrated eradication of prostate cancer with the antibody conjugated with DM1. Presumably one could speculate that Genentech and British Biotech had access to existing data on colon/pancreatic cancer trial which supported the deal making. The trial has dosed about 20(my guess) plus patients, some of whom are on their 4th dose with no side effects or immune system reaction. No word on efficacy but the people at IMGN are feeling good and are enthusiastic about TAP technology. Regards, JOE

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next